Q1 2026 · 13F-HR
Avidity Partners Management LPholdings as filed
Filed 2026-05-13 · accession 0001791827-26-000003
$441.9M
Reported value
46
Positions
2026-03-31
Period end
The Brief · Avidity Partners Management LP · Q1 2026
AI · grounded in 13F
Avidity Partners Management LP closed its position in CGON, reducing exposure by $61.1M. The fund established new positions in AKTS and VIR, with investments of $8.8M and $6.3M respectively. Additionally, the fund increased its holdings in PVLA by 262.7% and ELVN by 185.1%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $184.7M | 41.8% | 2,104,184 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $52.0M | 11.8% | 760,424 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $34.2M | 7.73% | 1,400,708 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $23.6M | 5.34% | 6,049,999 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $16.5M | 3.73% | 400,000 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $11.8M | 2.67% | 4,998,267 | Common | SOLE |
| 759916109 | RGEN | REPLIGEN CORP | $9.2M | 2.08% | 77,800 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $9.0M | 2.03% | 70,000 | Common | SOLE |
| 01021M104 | AKTS | AKTIS ONCOLOGY INC | $8.8M | 1.99% | 468,566 | Common | SOLE |
| G5960L103 | MDT | MEDTRONIC PLC | $8.1M | 1.83% | 100,000 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARMACEUTICAL INDS LTD | $7.0M | 1.59% | 200,000 | Common | SOLE |
| 4525EP101 | VTLUSD | IMMUNIC INC | $6.4M | 1.46% | 669,941 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $6.3M | 1.43% | 619,300 | Common | SOLE |
| 252131107 | DXCM | DEXCOM INC | $6.0M | 1.35% | 100,000 | Common | SOLE |
| 444859102 | HUM | HUMANA INC | $5.9M | 1.34% | 25,000 | Common | SOLE |
| 29261A100 | EHC | ENCOMPASS HEALTH CORP | $4.2M | 0.95% | 42,000 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $3.9M | 0.87% | 463,741 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $3.6M | 0.82% | 65,000 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $3.5M | 0.79% | 265,934 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORP | $3.5M | 0.78% | 60,000 | Common | SOLE |
| 80401L803 | MSLE | SATELLOS BIOSCIENCE INC | $3.1M | 0.70% | 387,769 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $2.8M | 0.63% | 249,390 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $2.6M | 0.59% | 20,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $2.0M | 0.45% | 48,000 | Common | SOLE |
| 811292200 | SCYX | SCYNEXIS INC | $1.9M | 0.44% | 2,081,660 | Common | SOLE |
| G4705A100 | ICLR | ICON PLC | $1.9M | 0.43% | 16,000 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $1.9M | 0.42% | 9,000 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $1.7M | 0.40% | 115,000 | Common | SOLE |
| 45784P101 | PODD | INSULET CORP | $1.7M | 0.39% | 10,000 | Common | SOLE |
| 159864107 | CRL | CHARLES RIV LABS INTL INC | $1.7M | 0.38% | 10,000 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $1.4M | 0.32% | 30,000 | Common | SOLE |
| 433000106 | HIMS | HIMS & HERS HEALTH INC | $1.4M | 0.31% | 50,000 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S | $1.3M | 0.30% | 50,000 | Common | SOLE |
| 70614W100 | PTON | PELOTON INTERACTIVE INC | $1.1M | 0.25% | 200,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $1.0M | 0.23% | 75,000 | Common | SOLE |
| M7518J104 | ODD | ODDITY TECH LTD | $1.0M | 0.23% | 70,000 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $922,500 | 0.21% | 150,000 | Common | SOLE |
| 002824100 | ABT | ABBOTT LABORATORIES | $907,900 | 0.21% | 10,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $819,000 | 0.19% | 50,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $711,100 | 0.16% | 10,000 | Common | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $525,000 | 0.12% | 125,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $368,804 | 0.08% | 43,853 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $352,800 | 0.08% | 15,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $291,109 | 0.07% | 12,967 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $262,000 | 0.06% | 50,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $91,642 | 0.02% | 6,660 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.